What is Bivalirudin?
Bivalirudin (brand name ANGIOMAX, originally called HIRULOG; development code BG8967) is a synthetic 20-amino-acid peptide direct thrombin inhibitor. It was approved by the FDA on December 15, 2000 for anticoagulation in patients undergoing percutaneous coronary intervention (PCI), particularly those with heparin-induced thrombocytopenia (HIT) or at risk for HIT.
Bivalirudin is a biomimetic engineered from hirudin, the natural anticoagulant peptide found in the saliva of the medicinal leech (Hirudo medicinalis). Where native hirudin is a 65-amino-acid protein produced by leeches and has been used in folk medicine for centuries, bivalirudin is a designed 20-amino-acid synthetic peptide that captures hirudin's key thrombin-binding domains in a smaller, manufacturable molecule.
Structure and Mechanism
Bivalirudin is a bivalent direct thrombin inhibitor:
- The N-terminal D-Phe-Pro-Arg-Pro tetrapeptide binds the thrombin catalytic site (active site)
- A flexible (Gly)4 linker
- The C-terminal hirudin-derived sequence (residues 53-64 of native hirudin) binds the thrombin anion-binding exosite I
This bivalent geometry produces:
- High affinity for thrombin (Ki ~2 nM)
- Reversible inhibition — the catalytic-site binding is slowly cleaved by thrombin, restoring thrombin activity
- Fibrin-bound thrombin inhibition — heparin-antithrombin complexes cannot inhibit clot-bound thrombin, but bivalirudin can
The reversible cleavage gives bivalirudin a predictable pharmacokinetic profile (half-life ~25 minutes) without requiring a specific reversal agent for most clinical scenarios.
Approved Indications
- Anticoagulation in patients with unstable angina undergoing PCI
- Anticoagulation in patients with or at risk of heparin-induced thrombocytopenia (HIT) undergoing PCI
- Anticoagulation in patients with HIT requiring PCI
Clinical Evidence
HORIZONS-AMI (NEJM 2008):
- 3,602 STEMI patients undergoing primary PCI
- Bivalirudin alone vs heparin + GPIIb/IIIa inhibitor
- Reduced major bleeding (4.9% vs 8.3%, p<0.001)
- Reduced 30-day net adverse clinical events
- 30-day mortality reduced
REPLACE-2:
- Bivalirudin + provisional GPIIb/IIIa inhibitor non-inferior to heparin + planned GPIIb/IIIa inhibitor
- Less major bleeding
Approval History
- December 15, 2000 — FDA approval (Angiomax, original liquid concentrate)
- 2014 — Generic bivalirudin approvals
- 2020 — Angiomax RTU (ready-to-use formulation) approved
Place in Therapy
Bivalirudin's primary niche is:
- PCI in patients with HIT or HIT history — the canonical indication where unfractionated heparin is contraindicated
- PCI in patients at high bleeding risk — bivalirudin's anticoagulation profile produces less bleeding than heparin + GPIIb/IIIa inhibitor in some studies
- Cardiopulmonary bypass with HIT — off-label but widely used
For routine PCI without HIT, bivalirudin's role has narrowed in recent years as low-cost generic heparin remains the workhorse, particularly with the decline in routine GPIIb/IIIa use.
Safety Profile
The most common adverse event is bleeding — overall lower than heparin + GPIIb/IIIa, but absolute bleeding remains the dominant safety concern. Other adverse events:
- Back pain (common but typically mild and transient)
- Hypotension
- Nausea
- Stent thrombosis with abrupt discontinuation (requires careful transition to oral anticoagulation when needed)
Why It Matters
Bivalirudin is one of the most successful examples of biomimetic peptide drug design — taking a complex natural protein (leech hirudin) and engineering a smaller, defined peptide that captures its key binding features in a synthetically tractable molecule. The resulting drug has been used in millions of cardiac procedures globally.